A single Covid project that’s not been renewed made an earnings dent in Merck KGaA’s manufacturing arm in the third ...
Investing.com -- Shares of Merck KGaA (ETR: MRCG) fell over 4% on Thursday following a mixed reception to its third-quarter ...
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...
(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...
Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, and Dr. Marjorie Green, senior vice president and ...
BusinessWire India Accra [Ghana] Mumbai Maharashtra [India] November 14 Merck Foundation the philanthropic arm of Merck KGaA ...
The German life-science and chemicals company attributed earnings growth to a recovery of its life-science segment, cost discipline and lower spending on research and development following the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback